BACKGROUND: Expansion of scope of practice and diminishing revenues from dispensing are requiring pharmacists to increasingly adopt clinical care services into their practices. Pharmacists must be able to receive payment in order for provision of clinical care to be sustainable. The objective of this study is to update a previous systematic review by identifying remunerated pharmacist clinical care programs worldwide and reporting on uptake and patient care outcomes observed as a result. METHODS: Literature searches were performed in several databases, including MEDLINE, Embase and International Pharmaceutical Abstracts, for papers referencing remuneration, pharmacy and cognitive services. Searches of the grey literature and Internet were also conducted. Papers and programs were identified up to December 2012 and were included if they were not reported in our previous review. One author performed data abstraction, which was independently reviewed by a second author. All results are presented descriptively. RESULTS: Sixty new remunerated programs were identified across Canada, the United States, Europe, Australia and New Zealand, ranging in complexity from emergency contraception counseling to minor ailments schemes and comprehensive medication management. In North America, the average fee provided for a medication review is $68.86 (all figures are given in Canadian dollars), with $23.37 offered for a follow-up visit and $15.16 for prescription adaptations. Time-dependent fees were reimbursed at $93.60 per hour on average. Few programs evaluated uptake and outcomes of these services but, when available, indicated slow uptake but improved chronic disease markers and cost savings. DISCUSSION: Remuneration for pharmacists' clinical care services is highly variable, with few programs reporting program outcomes. Programs and pharmacists are encouraged to examine the time required to perform these activities and the outcomes achieved to ensure that fees are adequate to sustain these patient care activities.
BACKGROUND: Expansion of scope of practice and diminishing revenues from dispensing are requiring pharmacists to increasingly adopt clinical care services into their practices. Pharmacists must be able to receive payment in order for provision of clinical care to be sustainable. The objective of this study is to update a previous systematic review by identifying remunerated pharmacist clinical care programs worldwide and reporting on uptake and patient care outcomes observed as a result. METHODS: Literature searches were performed in several databases, including MEDLINE, Embase and International Pharmaceutical Abstracts, for papers referencing remuneration, pharmacy and cognitive services. Searches of the grey literature and Internet were also conducted. Papers and programs were identified up to December 2012 and were included if they were not reported in our previous review. One author performed data abstraction, which was independently reviewed by a second author. All results are presented descriptively. RESULTS: Sixty new remunerated programs were identified across Canada, the United States, Europe, Australia and New Zealand, ranging in complexity from emergency contraception counseling to minor ailments schemes and comprehensive medication management. In North America, the average fee provided for a medication review is $68.86 (all figures are given in Canadian dollars), with $23.37 offered for a follow-up visit and $15.16 for prescription adaptations. Time-dependent fees were reimbursed at $93.60 per hour on average. Few programs evaluated uptake and outcomes of these services but, when available, indicated slow uptake but improved chronic disease markers and cost savings. DISCUSSION: Remuneration for pharmacists' clinical care services is highly variable, with few programs reporting program outcomes. Programs and pharmacists are encouraged to examine the time required to perform these activities and the outcomes achieved to ensure that fees are adequate to sustain these patient care activities.
Authors: Natasha Matheny Michaels; Gretchen F Jenkins; Debra L Pruss; Joe E Heidrick; Stefanie P Ferreri Journal: J Am Pharm Assoc (2003) Date: 2010 May-Jun
Authors: John M Brooks; Elizabeth J Unni; Donald G Klepser; Julie M Urmie; Karen B Farris; William R Doucette Journal: Res Social Adm Pharm Date: 2008-08-08
Authors: Vanita K Pindolia; Lesia Stebelsky; Tanya M Romain; Lori Luoma; Sandra N Nowak; Fadwa Gillanders Journal: Ann Pharmacother Date: 2009-03-31 Impact factor: 3.154
Authors: Lynette Kosar; Nianping Hu; Lisa M Lix; Yvonne Shevchuk; Gary F Teare; Anne Champagne; David F Blackburn Journal: Can Pharm J (Ott) Date: 2017-11-29
Authors: Lisa Dolovich; Giulia Consiglio; Linda MacKeigan; Lusine Abrahamyan; Petros Pechlivanoglou; Valeria E Rac; Nedzad Pojskic; Elizabeth A Bojarski; Jiandong Su; Murray Krahn; Suzanne M Cadarette Journal: Can Pharm J (Ott) Date: 2016-08-09
Authors: Aranzazu Noain; Victoria Garcia-Cardenas; Miguel Angel Gastelurrutia; Amaia Malet-Larrea; Fernando Martinez-Martinez; Daniel Sabater-Hernandez; Shalom I Benrimoj Journal: Int J Clin Pharm Date: 2017-04-22
Authors: Sherilyn K D Houle; Theresa L Charrois; Finlay A McAlister; Michael R Kolber; Meagen M Rosenthal; Richard Lewanczuk; Norman R C Campbell; Ross T Tsuyuki Journal: Can Pharm J (Ott) Date: 2016-10-03